Product Description
HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses
Mechanisms of Action: TNF Inhibitor,IL1 Inhibitor,IL6 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HUTCHMED
Company Location: HONG KONG K3 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colitis, Ulcerative
Phase 2: Crohn Disease|Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2017-599-00AU1 | P1 |
Terminated |
Crohn Disease|Colitis, Ulcerative |
2018-11-19 |
22% |
HMPL-004-03 | P3 |
Terminated |
Colitis, Ulcerative |
2014-10-01 |
|
NATRUL-4 | P3 |
Terminated |
Colitis, Ulcerative |
2014-10-01 |
81% |
2013-003060-31 | P3 |
Terminated |
Colitis, Ulcerative |
2014-08-13 |